Most cancer therapies work for only a subset of patients, yet treatment decisions still rely on trial-and-error approaches. Solid IO is changing this by replicating a patient’s tumor biology ex vivo, enabling real-time, personalized therapy guidance.

Our proprietary organ-on-chip technology mimics the tumor microenvironment, providing actionable data on patient response to immunotherapies. Unlike conventional models, our approach preserves patient-specific immune interactions, offering a breakthrough in therapy selection.

We focus on solid cancers, where immunotherapies are widely used but lack reliable response prediction. Our goal is to integrate this technology into clinical decision-making world-wide.

Solid IO is actively seeking partners for clinical validation and co-development. With support from EIT EP PerMed, we aim to accelerate validation, ensuring that in the future, IO treatments are not only accessible, but every patient gets the right treatment – every time.